Study of real-world treatment patterns and adherence to bacillus Calmette-Guerin (BCG) in the context of guideline recommendations for patients with high-risk non-muscle invasive bladder cancer (NMIBC).

Authors

Franklin D Gaylis

Genesis Healthcare Partners, San Diego, CA

Franklin D Gaylis , Bruno Emond , Ameur M Manceur , Anabelle Tardif-Samson , Laura Morrison , Dominic Pilon , Patrick Lefebvre , Lorie Ellis , Hiremagalur parthasarathy Balaji , Andrea Ireland

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Population based trends in intravesical gemcitabine use among patients with high-risk non-muscle invasive bladder cancer.

First Author: Stephen B. Williams

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.

First Author: Gary D. Steinberg

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Guiding adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient-derived organoids.

First Author: Martin Egger

insert_chart_outlined

Poster

2022 ASCO Quality Care Symposium

bookmark_border

Real-world treatment patterns among patients with non-muscle invasive bladder cancer (NMIBC) treated with intravesical Bacillus Calmette-Guerin (BCG).

First Author: Neela Kumar